placebo + lapatinib + capecitabine

This combination refers to the control arm of the Phase 2 APRiCOT-B clinical trial (NCT00657137), sponsored by Tragara Pharmaceuticals. It involves the administration of a placebo (matching the COX-2 inhibitor apricoxib) in conjunction with the standard-of-care regimen of lapatinib and capecitabine for patients with HER2-positive breast cancer. Lapatinib is a dual tyrosine kinase inhibitor that targets the intracellular domains of the Human Epidermal Growth Factor Receptor 2 (HER2) and the Epidermal Growth Factor Receptor (EGFR). Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), which acts as an antimetabolite by inhibiting thymidylate synthase and interfering with DNA and RNA synthesis. The trial specifically targeted patients who had previously failed treatment with trastuzumab and taxane-based chemotherapy.

Brand names

Xeloda

Other names

placebo plus lapatinib and capecitabinecontrol arm of APRiCOT-B